



New Data Presented at ISPOR Shows Ultrafiltration Therapy Demonstrates a Cost Savings of \$3,975 Per Patient at 90 Days

May 24, 2018

EDEN PRAIRIE, Minn., May 24, 2018 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (Nasdaq:CHFS) announced today that a cost analysis¹ from the hospital perspective showed substantial cost savings at 90 days when using an ultrafiltration system versus diuretic therapy. This research was presented in a poster session at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) conference on Wednesday, May 23, 2018 at the Baltimore Convention Center, Baltimore, Md.

The cost-analysis model used a decision analytic framework to reflect treatment decisions, probabilistic outcomes, and associated costs for treating heart failure patients suffering from fluid overload with either ultrafiltration or intravenous diuretics. The data presented demonstrates that although initial hospital costs were higher in the ultrafiltration arm due to the cost of the system itself, fluid removal by ultrafiltration led to reduced hospital readmission days which resulted in a cost savings of \$6,148 per patient. The aggregate cost savings with ultrafiltration over 90 days, including initial hospital costs, were \$3,975 or 14.4% per patient. Despite higher upfront costs, ultrafiltration reduced hospital cost via readmission rates and durations, over a 90-day period compared to diuretic therapy.

"Limited data exists on costs associated with the use of alternative therapies to treat patients with fluid overload," said John Erb, chairman and chief executive officer of CHF Solutions. "We are encouraged by the data presented at ISPOR which provides new supporting evidence on the potential cost savings of ultrafiltration. Importantly, the data provides physicians additional evidence when considering appropriate therapy for treating fluid overload in heart failure patients that are diuretic resistant."

About CHF Solutions

CHF Solutions, Inc. (NASDAQ:CHFS) is a medical device company focused on commercializing the Aquadex FlexFlow system for Aquapheresis® therapy. The Aquadex FlexFlow system is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies. The company's mission is to predict, measure, and control patient fluid balance through science, collaboration, and innovative medical technology. CHF Solutions is a Delaware corporation headquartered in Minneapolis, Minnesota with wholly owned subsidiaries in Australia and Ireland. The company has been listed on the NASDAQ Capital Market since February 2012.

¹ Costanzo MR, et al. Ultrafiltration vs. Diuretics for the Treatment of Fluid Overload in Patients with Heart Failure: A Hospital Cost Analysis. Poster accepted for presentation at the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) International Meeting, May 19-23, 2018, Baltimore, MD, USA

CONTACTS:

INVESTORS:

Claudia Napal Drayton
Chief Financial Officer
CHF Solutions, Inc.
952-345-4205
ir@chf-solutions.com

-or-

Bret Shapiro
Managing Partner
CORE IR
516-222-2560
brets@coreir.com
www.coreir.com

MEDIA

Jules Abraham
JQA Partners, Inc.
917-885-7378
jabraham@jqapartners.com

[Primary Logo](#)

Source: CHF Solutions, Inc.